RZLT — Rezolute, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1509261 ·
Last close
$4.75
Market Cap
$457.39M
52W High
$5.42
52W Low
$2.83
ADV30
2,438,501
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -17,366,000 | -16,171,000 | 125,459,000 | 11,236,000 | 8,625,000 |
| Dec 2025 | 0 | — | -24,221,000 | -22,774,000 | 138,629,000 | 11,944,000 | 10,631,000 |
| Sep 2025 | 0 | — | -19,817,000 | -18,150,000 | 158,664,000 | 9,098,000 | 11,496,000 |
| Jun 2025 | 0 | — | -25,850,000 | -24,390,000 | 175,490,000 | 94,107,000 | 13,363,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-73,484,000
Investing CF
$-33,050,000
Financing CF
$103,174,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.82
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-460,951,000
Inventory
—
Receivables
—
ST Investments
$109,032,000
EBIT TTM
$-87,254,000
Pretax Income TTM
$-81,485,000
Interest Exp TTM
—
Analysts
9
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Jun 2025 | 0 | -79,894,000 | -74,412,000 | 175,490,000 | 13,363,000 | — | -69,075,000 |
| Jun 2024 | 0 | -70,423,000 | -68,459,000 | 132,737,000 | 11,734,000 | — | -57,368,000 |
| Jun 2023 | 0 | -55,990,000 | -51,787,000 | 123,721,000 | 7,549,000 | — | -44,481,000 |
| Jun 2022 | 0 | -41,612,000 | -41,060,000 | 152,420,000 | 2,949,000 | — | -39,616,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.63
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BNTC | Benitec Biopharma Inc. | $461.04M | $13.42 | — |
| SGMT | Sagimet Biosciences Inc. | $450.93M | $7.37 | — |
| TENX | TENAX THERAPEUTICS, INC. | $465.52M | $17.55 | — |
| OVID | Ovid Therapeutics Inc. | $470.33M | $2.52 | — |
| LRMR | Larimar Therapeutics, Inc. | $444.62M | $4.28 | — |
News headlines (Yahoo Finance, 1h cache)
Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society
2026-06-17 11:00 · Yahoo
Exploring 3 High Growth Tech Stocks in US Market
2026-06-15 11:39 · Yahoo
Positive Signs As Multiple Insiders Buy Rezolute Stock
2026-06-10 11:46 · Yahoo
RZLT Stock on the Move: What Sparks the 38% Jump in the Past Week?
2026-06-04 15:58 · Yahoo
Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society
2026-06-04 11:30 · Yahoo
Yum! Brands upgraded, Chipotle downgraded: Wall Street's top analyst calls
2026-06-03 13:55 · Yahoo
Rezolute’s stock up on interim Phase III tumour HI data
2026-06-03 11:47 · Yahoo
Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
2026-06-02 11:00 · Yahoo
High Growth Tech Stocks in US for May 2026
2026-05-14 11:38 · Yahoo
Rezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
2026-05-12 20:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.